Background: Lupus nephritis (LN) is a feared complication of systemic lupus erythematosus (SLE). Renal biopsy is valuable to assess disease severity and prognosis, but no histological data are available for Indigenous Australians (IA). We compared histopathology between IA and non-IA patients (NI) with LN in northern Australia and describe main outcomes.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease that occurs more frequently in Indigenous Australians (IA). [1] [2] [3] Lupus nephritis (LN) is a major complication that usually develops early in the disease course and is more frequent and severe in non-Caucasian patients, where it carries a 5-20% risk of progression to end-stage renal disease (ESRD). 4, 5 Earlier studies described a high frequency of clinical manifestations of LN in IA patients, 2, 3 but there are no data on the underlying renal histopathology in IA. 6 This study investigated the incidence, histological characteristics and clinical outcome of LN in the largest hospital of the Northern Territory (NT), Australia, where approximately 27% of the population identifies as IA. 7 
PATIENTS AND METHODS
Inclusion criteria for the current study were the presence of an adequate biopsy specimen (containing at least eight non-sclerotic glomeruli) obtained between January 2001 and December 2011 with a histological diagnosis of LN as determined by a renal pathologist in patients fulfilling the revised American College of Rheumatology (ACR) classification criteria for SLE. 8 Patients were identified through two supplemental sources at the Royal Darwin Hospital (the Lab Track pathology database and the NT SLE registry). Demographic details (gender, date of birth and ethnicity), date of SLE diagnosis (i.e., date of cumulatively fulfilling four ACR criteria), date of first renal biopsy, histological findings, renal function on last visit, starting date of dialysis and date of death were retrieved by chart review using a predefined form. Patients resided in the northern quarter ('Top End') of the NT encompassing Darwin, Palmerston, Katherine, Gove, Tiwi Islands and Groote Eylandt. Australian Bureau of Statistics (ABS) definitions were used to classify patients as 'Indigenous', 'Caucasian' or 'Asian' with the term 'Indigenous' referring to all persons who identified as being of Aboriginal, Torres Strait Islander or both Aboriginal and Torres Strait Islander origin. Ethics approval was obtained from Menzies School of Health, Human Research Ethics Committee (HREC 10-1422).
Indications for renal biopsies were new-onset proteinuria > 0.5 g/day and/or increasing proteinuria and/ or renal failure and/or active urinary sediment in new or established SLE patients. 9 Renal specimens were assessed by light microscopy (LM), immunofluorescence (IF) and electron microscopy (EM). We recorded the type of immune deposits (immunoglobulin [Ig]G, IgM, IgA, C3, C1q and fibrin) and localization in mesangial or capillary walls with fluorescence intensity scored on a semi-quantitative scale (0 = none, 1 = weakly positive, 2 = positive, 3 = strongly positive) and the number and distribution (sub-epithelial, sub-endothelial or transmembranous) of electron-dense deposits (EDD). Based on combined LM/IF and EM findings, biopsies were graded according to the International Society of Nephrology (ISN) pathologic classification scheme for LN. 10 For the purpose of this analysis, mixed Classes III + V and Classes IV + V nephritis were regarded as Class III and Class IV respectively, while National Institutes of Health activity index (NIH-AI) (range 0-24) and chronicity index (NIH-CI) (range 0-12) were separately estimated. Only first biopsy findings were included in the main analyses with the date of the first renal biopsy taken as the starting point for life table estimates. Treatment consisted of OH-chloroquine, prednisolone and methotrexate use for extra-renal manifestations in patients with Class I and II lesions and hydrochloroquine, prednisolone (up to 1 mg/kg) and mycophenolate or cyclophosphamide for patients with proliferative LN (Class III/IV) in accordance with current recommendations. 11 Angiotensinconverting enzyme (ACE)-inhibitor treatment was preferred for arterial hypertension. Outcome measures were death as ascertained by electronic health records and ESRD as the documented need for chronic (> 3 months) renal replacement therapy or transplantation, while renal insufficiency was defined as recorded sustained doubling of serum creatinine for at least 6 months. 12 
Statistical analysis
Numbers given are median values (interquartile range) unless otherwise stated. Incidence statistics were based on Australian Bureau of Statistics 2011 census population data given as annual incidence (AI) per 100 000. Continuous data were analyzed with the use of non-parametric tests and Chi-square test for grouped variables. Survival curves were constructed with Kaplan-Meier life-table estimates and compared by log rank test with non-survivors censored from the renal survival curves from the date of death. Significant predictors from univariate analyses were then entered into a multivariate backward logistic regression analysis (P < 0.2 to enter, P < 0.05 to stay) to determine if they independently predicted the outcome (hazard ratio with 95% CI). SPSS v.21 software (IBM, Armonk, NY, USA) was used for data analysis with resulting P-values ≤ 0.05 as the definition of statistical significance.
RESULTS
Fifty-nine renal biopsies were identified in 45 patients. Three patients were excluded as the initial biopsy contained two glomeruli (one) or histology was not consistent with LN (two) and 14 biopsies were repeat biopsies. Clinical characteristics for the cohort (n = 42) at the time of first biopsy (Table 1 ) showed a 6:1 female-to-male ratio and an Indigenous, Asian and Caucasian background in 74%, 2.4% and 23.6%, respectively. The estimated annual incidence rate of biopsy-proven LN was 2.1/100 000 overall, and much higher in the IA (7/100 000) compared to the nonIndigenous (NI) population (0.7/100 000).
Disease duration at biopsy was 8 months (range 0-102) and LN was a first presentation of SLE in 21.4% of patients. The time from SLE diagnosis to renal biopsy was shorter in IA than NI patients (13 vs. 35 months; P = 0.001). Antinuclear antibodies were detected in 97.5%, anti-double-stranded DNA (anti-dsDNA) antibodies in 63% and hypocomplementemia in 75% of patients, while elevated serum creatinine (> 100 lmol/L) at biopsy was present in 24% with no significant differences between IA and NI patients (all P-values > 0. 2) Proliferative LN (Class III or IV) was more frequent in NI patients (72% vs. 42%, P = 0.01) (Fig. 1) , while the NIH-AI (3.7 vs. 5.2, P = 0.06) and NIH-CI (1.73 vs. 1.87, P = 0.7) did not differ between IA and NI patients (Table 1 ). In contrast, a 'full-house' pattern of immune complex deposits was seen in more IA than NI patients (79% vs. 21%, P < 0.05), with no difference in the number or localization of EDD between NI and IA patients (Table 1) .
Fourteen repeat biopsies were performed in 10 patients; four were in NI patients (36%) and six in IA patients (19%). Median time between first and second biopsies was 16 months (range 7-106) with one patient undergoing three and two patients undergoing two repeat biopsies. Classification of the last biopsy findings ( Table 2) had not changed in 50%, two patients (one from Class II and one from Class IV) had progressed to Class IV, one patient transformed from Class III to Class V and two patients had regressed from Class IV to Classes II and III.
After a mean follow-up of 68 months (range 3-170) ESRD had developed in 19% of IA patients but none of the NI patients (P < 0.01) Renal survival rates after 5 and 10 years were 83% and 53% versus 100% and 100%, respectively (P = 0.08) (Fig. 2A) . There was no demonstrable effect on renal survival for gender, age > 30 years at biopsy, proliferative versus non-proliferative LN, NIH-AI ≥ 6, NIH-CI ≥ 3, anti-dsDNA positivity or hypocomplementemia (all P-values > 0.2). Doubling of initial serum creatinine levels occurred in another 19% of IA patients and in 9% of NI patients (P = 0.6) ( Table 2 ). Patient survival rates at 5 and 10 years were 69% and 50% for IA and 90% for NI, respectively (P = 0.08) (Fig. 2b) 
DISCUSSION
This first report on the renal histopathology of LN in IA patients confirms a higher prevalence of LN in the IA population with a lower degree of renal inflammation despite a larger burden of renal immune deposits. The estimate for LN incidence in the Caucasian population (0.7/100 000) in this study is largely in agreement with LN incidence rates observed in similar populations in the UK (0.4) and Scandinavia (0.5). 13, 14 The incidence rate of LN in the IA population markedly exceeded that for Caucasians in this region, but also exceeds LN rates reported in African American or Pacific Islander and Maori populations. 15, 16 It should be noted that these figures should be considered minimum estimates of LN incidence based on histological evidence of LN, while the rate of clinically evident LN varies in IA populations but may be up to 20% higher. [1] [2] [3] 13 Despite this limitation, the significantly increased LN susceptibility in IA is remarkable and while this could be due to genetically determined factors, it is likely that environmental factors also contribute to this predisposition. Lifetime UV exposure and rates of scabies, Streptococcal, Strongyloides and Mycobacterium infections are higher in northern Australian communities and together could increase LN susceptibility as these have been associated with significantly higher serum levels of immunoglobulins, anti-dsDNA antibody presence and renal mesangial proliferation. [17] [18] [19] This would be compatible with the intriguing observation that Class II LN (i.e., mesangial proliferation) was more frequently observed in IA patients and further supported by the lower AI score observed in this group. Together this indicates a lower inflammatory renal burden at the time of biopsy in IA patients and suggests that despite a similar prevalence of anti-dsDNA antibodies, much of the increased renal immune deposits in this group of IA patients did not contain nephritogenic auto-antibodies. 17 An alternative explanation for the observed lower renal inflammatory burden could be the shorter interval between disease onset and renal biopsy in the IA patients. As nephritogenic anti-dsDNA antibodies arise through a process of affinity maturation over time, 20 clinician concern over the overall renal vulnerability in IA for hypertensive and metabolic complications 21 may have led to diagnostic intervention too early to capture full-blown LN and led to under treatment. However, the relatively low rate of class transformation and disease progression on repeat biopsies with no obvious difference between IA and NI patients would argue against this consideration, while expert opinion also recommends early renal biopsy in the face of urinary abnormalities. 22 Despite the lower burden of inflammation at biopsy, the outcomes for IA patients were poor compared to the NI patients and also lower than the reported 5-year survival in Texan Hispanics and African Americans. 5 The reasons for this increased risk of death and progression to ESRD are likely multifactorial; the majority of our IA cohort belonged to disadvantaged communities, where low socio-economic status, poor compliance and a high prevalence of comorbidity such as arterial hypertension and diabetes mellitus impact on the prognosis. 18, 23 The observed survival disparity is not unique to LN as it is also seen in IA patients with cancer or receiving renal replacement therapy. [24] [25] [26] [27] The fact that LN class and renal activity index or serological disease measures were not predictive of renal survival strongly suggests that factors other than histological LN severity contribute to this poor renal prognosis. We did not study the extent of comorbidity as it was outside the main scope of our paper, but our results indicate that further investigation is needed to determine the exact role of LN and comorbid conditions in this context. This will require a larger, longitudinal and controlled study with more detailed follow-up information.
The two most common causes of death in this cohort were infections and ESRD (38% and 23%, respectively). While nearly all patients were started on immunomodulating treatment, we did not have access to the remote clinic data to determine if and how this could have contributed to infection risk. However, the overall frequency of fatal infections is in agreement with reports on SLE cohort studies worldwide, where infections also make up approximately a third of all fatalities. 28, 29 The rate of ESRD-related death was higher than reported elsewhere and this may be due to comorbidity, accessibility and/or reluctance to start and continue renal replacement therapy as illustrated by the two IA patients that chose to discontinue dialysis.
There are inherent limitations in this study due to the small cohort size and its retrospective nature. The analysis examined baseline characteristics rather than changes in disease-specific data such as treatment changes or autoantibody and complement levels during the disease course. Our biopsy-proven LN incidence estimates are based on best available evidence from the Australian Bureau of Statistics, and although Indigenous status is well identified in the NT, shifting definitions of IA and uncertainty regarding census data for remote Indigenous communities must be taken into consideration. We also did not collect data on comorbid conditions, social and economic circumstances which together with the lack of a control group makes it difficult to accurately assess the extent to which LN independently contributed to mortality and ESRD development.
In conclusion, the incidence and outcome of LN in the Caucasian population of the NT did not differ from findings in other Western populations. In contrast, renal biopsy findings consistent with LN were much more frequently seen in the IA population. In IA patients a higher burden of renal immune complex deposition and a lower burden of renal inflammation were observed, but could not be directly linked to worse renal and patient outcomes.
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